Guardant Health (GH) Competitors $50.25 +0.07 (+0.14%) Closing price 07/3/2025 02:58 PM EasternExtended Trading$50.50 +0.25 (+0.50%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GH vs. VCYT, NTRA, FMS, HIMS, OPCH, RDNT, BTSG, SHC, SGRY, and PRVAShould you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Veracyte (VCYT), Natera (NTRA), Fresenius Medical Care AG & Co. KGaA (FMS), Hims & Hers Health (HIMS), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry. Guardant Health vs. Its Competitors Veracyte Natera Fresenius Medical Care AG & Co. KGaA Hims & Hers Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Privia Health Group Veracyte (NASDAQ:VCYT) and Guardant Health (NASDAQ:GH) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment. Which has more risk & volatility, VCYT or GH? Veracyte has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Do insiders and institutionals hold more shares of VCYT or GH? 92.6% of Guardant Health shares are held by institutional investors. 1.4% of Veracyte shares are held by company insiders. Comparatively, 6.1% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, VCYT or GH? Veracyte has higher earnings, but lower revenue than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$445.76M4.83$24.14M$0.4167.10Guardant Health$739.02M8.42-$436.37M-$3.39-14.82 Does the media prefer VCYT or GH? In the previous week, Guardant Health had 7 more articles in the media than Veracyte. MarketBeat recorded 11 mentions for Guardant Health and 4 mentions for Veracyte. Guardant Health's average media sentiment score of 0.72 beat Veracyte's score of 0.56 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Guardant Health 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is VCYT or GH more profitable? Veracyte has a net margin of 7.13% compared to Guardant Health's net margin of -53.82%. Veracyte's return on equity of 6.14% beat Guardant Health's return on equity.Company Net Margins Return on Equity Return on Assets Veracyte7.13% 6.14% 5.60% Guardant Health -53.82%N/A -26.77% Do analysts rate VCYT or GH? Veracyte presently has a consensus target price of $40.90, suggesting a potential upside of 48.67%. Guardant Health has a consensus target price of $53.76, suggesting a potential upside of 6.99%. Given Veracyte's higher possible upside, equities research analysts clearly believe Veracyte is more favorable than Guardant Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Guardant Health 0 Sell rating(s) 0 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVeracyte and Guardant Health tied by winning 8 of the 16 factors compared between the two stocks. Get Guardant Health News Delivered to You Automatically Sign up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GH vs. The Competition Export to ExcelMetricGuardant HealthMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.26B$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-14.8221.5627.5220.22Price / Sales8.42281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book-44.477.518.045.67Net Income-$436.37M-$55.05M$3.18B$249.13M7 Day Performance-1.20%4.61%2.90%3.28%1 Month Performance3.80%4.72%3.70%5.55%1 Year Performance74.78%5.92%36.15%21.12% Guardant Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHGuardant Health3.7456 of 5 stars$50.25+0.1%$53.76+7.0%+76.9%$6.26B$739.02M-14.822,021Insider TradeVCYTVeracyte3.6097 of 5 stars$27.03-1.3%$40.90+51.3%+28.1%$2.12B$463.39M65.93790NTRANatera2.1651 of 5 stars$168.94+0.6%$184.63+9.3%+44.7%$23.07B$1.70B-114.923,020Positive NewsInsider TradeFMSFresenius Medical Care AG & Co. KGaA2.55 of 5 stars$28.60+1.4%$27.80-2.8%+46.2%$16.78B$19.49B25.541,384Positive NewsHIMSHims & Hers Health2.2054 of 5 stars$49.94+1.1%$39.58-20.7%+133.8%$11.18B$1.48B72.381,637Trending NewsInsider TradeOPCHOption Care Health4.3657 of 5 stars$32.48+0.7%$35.50+9.3%+11.5%$5.32B$5.00B26.198,088Positive NewsRDNTRadNet3.6791 of 5 stars$56.91-0.4%$69.60+22.3%-5.2%$4.27B$1.83B-132.3511,021BTSGBrightSpring Health Services1.6305 of 5 stars$23.59+0.2%$24.90+5.6%+95.5%$4.15B$11.27B84.2535,000SHCSotera Health3.0002 of 5 stars$11.12-1.8%$16.00+43.9%+0.8%$3.16B$1.10B139.023,000SGRYSurgery Partners2.6015 of 5 stars$22.23+1.3%$33.56+50.9%-6.1%$2.85B$3.17B-14.5315,000PRVAPrivia Health Group4.2461 of 5 stars$23.00+4.5%$27.77+20.7%+30.4%$2.80B$1.74B191.681,140High Trading Volume Related Companies and Tools Related Companies Veracyte Alternatives Natera Alternatives Fresenius Medical Care AG & Co. KGaA Alternatives Hims & Hers Health Alternatives Option Care Health Alternatives RadNet Alternatives BrightSpring Health Services Alternatives Sotera Health Alternatives Surgery Partners Alternatives Privia Health Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GH) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guardant Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
